Bb536 clinical evidence

BB536 Clinical Evidence
Contents
Digestive Support ................................................................................... 1 Restoration of Healthy Microflora .......................................................... 10 Normal Response to Inflammation ........................................................ 11 Seasonal Relief..................................................................................... 12 Healthy Immune Support ...................................................................... 17 Cellular Health ...................................................................................... 20 Healthy Cholesterol Levels .................................................................... 22 Infant Health......................................................................................... 23

Digestive Support
Bioscience Microflora Ogata T., et al. Effect of Bifidobacterium longum BB536 administration on the intestinal environment, defecation frequency, and fecal characteristics of human volunteers. 1997. 16(2): 53-58. Topic: Does Bifidobacterium longum BB536 have an effect on intestinal environment, defecation frequency, and fecalcharacteristics? Background: Bifidobacterium is a genus of Gram-positive, anaerobic bacteria. They are ubiquitous inhabitants of the gastrointestinal tract, vagina and mouth of mammals and other animals. Many species of bifidobacteria exert a range of beneficial health effects, including the regulation of intestinal microbial homeostasis, the inhibition of pathogens and harmful bacteria that colonizeand/or infect the gut mucosa, the modulation of local and systemic immune responses, the repression of procarcinogenic enzymatic activities within the microbiota, the production of vitamins, and the bioconversion of a number of dietary compounds into bioactive molecules. The study investigates BB536, a strain of bifidobacteria used in many dairy products, on intestinal health. Study type: Humanclinical intervention trial Study design: Placebo-controlled crossover study. Study 1: Volunteers consumed 200 mL of milk per day for 1 week (control period). After an interval period of 2 weeks, they were assigned to group A or group B and served 200 mL of milk containing B. longum BB536 at concentrations of either 2 x 109 (group A) or 2 x 1010 (group B) for 1 week. Parameters of intestinal environmentwere measured after control period and after treatment period. Study 2: Volunteers consumed 200 mL of milk per day for 1 week (control period). After an interval period of 2 weeks, they were served 200 mL of milk containing B. longum BB536 at a concentration of 2 x 109 for 3 weeks. Defecation frequency was monitored and visual fecal characteristics were observed during control period and duringtreatment period. Subjects: Study 1 - intestinal environment: 12 volunteers Study 2 - defecation frequency and fecal characteristics: 40 female volunteers suffering from constipation Dosage: 2 x 109 or 2 x 1010 viable B. longum BB536 cells daily in 200 mL of milk Results: The administration of B. longum BB536 resulted in the following changes compared with control period: • A significant decreaseof fecal ammonia content. • A significant reduction in the activity of some fecal enzymes. • An increase in Bifidobacterium percentage in the fecal flora. • A decrease in the number of Enterobacteriaceae and Clostridium perfringens. • A significant increase in fecal moisture content. • A significant increase in the defecation frequency. • A positive change in the fecal visualcharacteristics. Conclusion: “The results indicate that the administration of B. longum BB536 improves intestinal environment, defecation frequency, and fecal characteristics.”

1

914.251.0701 x.144

BB536 Clinical Evidence
Digestive Support
Anaerobe Odamaki T., et al. Effect of the oral intake of yogurt containing Bifidobacterium longum BB536 on the cell numbers of enterotoxigenic Bacteroides...